Possible Roles of Mitochondrial Dynamics and the Effects of Pharmacological Interventions in Chemoresistant Ovarian Cancer.
Possible Roles of Mitochondrial Dynamics and the Effects of Pharmacological Interventions in Chemoresistant Ovarian Cancer.
复制标题
DOI：
10.1016/j.ebiom.2018.07.026
复制
发表时间：
2018-08
期刊：
影响因子：
11.1
通讯作者：
Chattipakorn SC
中科院分区：
文献类型：
--
作者：
Kingnate C;Charoenkwan K;Kumfu S;Chattipakorn N;Chattipakorn SC
卵巢癌是所有妇科癌症中的主要死亡原因。这种癌症的预后很差，因为患者只有在晚期才寻求治疗。这种癌症的任何早期生物标志物仍然未知。线粒体动力学失调与相关的抗凋亡在几种类型的人类癌症发生中起着至关重要的作用，包括卵巢癌。先前的研究表明，卵巢癌细胞中发生线粒体分裂增加。然而，通过促进癌细胞的线粒体分裂和凋亡来改变线粒体动力学的几种药理学干预和治疗策略已被证明在卵巢癌治疗中可能提供有益的效果。因此，本综述的目的是总结和讨论目前的研究结果，在体外，体内和临床研究与线粒体动力学的改变和卵巢癌的干预和不干预。线粒体动力学失调发生在卵巢癌。线粒体失调的增加可能与卵巢癌化疗耐药程度的增加有关。药物诱导的线粒体分裂和凋亡将在卵巢癌治疗中发挥有益的作用。
Ovarian cancer is the major cause of death out of all the gynecologic cancers. The prognosis of this cancer is quite poor since patients only seek treatment when it is at an advanced stage. Any early biomarkers for this cancer are still unknown. Dysregulation of mitochondrial dynamics with associated resistance to apoptosis plays a crucial role in several types of human carcinogenesis, including ovarian cancers. Previous studies showed that increased mitochondrial fission occurred in ovarian cancer cells. However, several pharmacological interventions and therapeutic strategies, which modify the mitochondrial dynamics through the promotion of mitochondrial fission and apoptosis of cancer cells, have been shown to potentially provide beneficial effects in ovarian cancer treatment. Therefore the aim of the present review is to summarize and discuss the current findings from in vitro, in vivo and clinical studies associated with the alteration of mitochondrial dynamics and ovarian cancers with and without interventions. Dysregulation of mitochondrial dynamics occurred in ovarian cancer. Increased mitochondrial dysregulation may correlate with the increasing degree of chemoresistance in ovarian cancers. Drugs-induced mitochondrial fission and apoptosis will be beneficial effect in ovarian cancer therapy.
登录
查看更多内容
影响因子：
9
作者：
Chowdhury SR;Ray U;Chatterjee BP;Roy SS
通讯作者：
Roy SS
DOI：
10.1016/j.beem.2012.05.003
发表时间：
2012-12
期刊：
Best practice & research. Clinical endocrinology & metabolism
影响因子：
--
作者：
Osellame LD;Blacker TS;Duchen MR
通讯作者：
Duchen MR
DOI：
10.4196/kjpp.2018.22.2.203
发表时间：
2018-03
期刊：
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
影响因子：
--
作者：
Kim DY;Jung SY;Kim YJ;Kang S;Park JH;Ji ST;Jang WB;Lamichane S;Lamichane BD;Chae YC;Lee D;Chung JS;Kwon SM
通讯作者：
Kwon SM
影响因子：
4.8
作者：
Farrand, Lee;Byun, Sanguine;Tsang, Benjamin K.
通讯作者：
Tsang, Benjamin K.
影响因子：
4
作者：
Li, Lan;He, Li;Tang, Hua
通讯作者：
Tang, Hua